



ENFLONIA™
(clesrovimab-cfor) 105 mg injection

ENFLONIA IS AVAILABLE TO ORDER TODAY.

Order ENFLONIA now for your appropriate patients. ENFLONIA is designed to protect infants against a spectrum of RSV lower respiratory tract disease severity, including worsening disease requiring hospitalization.



ENFLONIA is recommended by CDC's ACIP and AAP as an option for the prevention of respiratory syncytial virus (RSV) in infants younger than 8 months of age born during or entering their first RSV season. See below for additional insights on how to order ENFLONIA via public and private sectors.^{1,2}

- For private-sector ordering, visit ordering.merckvaccines.com or contact a Merck Authorized Distributor.
- For public-sector ordering, ENFLONIA is available through the Vaccines for Children (VFC) Program in most states. Please reach out to your local awardee for more information on product availability.

Single doses available!



Not actual size shown



Merck currently has adequate supply of ENFLONIA for the 2025-2026 RSV season.

Indications and Usage

ENFLONIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Selected Safety Information

Do not administer ENFLONIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONIA.

Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

(Selected Safety Information continues on next page)

Information you should know when ordering

Recommended dosage

Neonates and infants: First RSV season

- The recommended dose is 105 mg administered as a single intramuscular (IM) injection.
- For neonates and infants born during the RSV season, administer ENFLONSIA once starting from birth. For infants born outside the RSV season, administer ENFLONSIA once prior to the start of their first RSV season considering the duration of protection provided by ENFLONSIA.

Infants undergoing cardiac surgery with cardiopulmonary bypass

- For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose administered as an IM injection is recommended as soon as the infant is stable after surgery to ensure adequate clesrovimab-cfor serum levels.

Supply options

ENFLONSIA injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution supplied as follows:

- Carton containing one or ten single-dose prefilled type I glass syringe(s) with Luer Lock and plunger stopper. The prefilled syringe is not made with natural rubber latex.



Not actual size shown

Prefilled syringe	Pack size	NDC
105 mg/0.7 mL single-dose	Carton of 1	10-Digit: 0006-5073-01 11-Digit: 00006-5073-01
105 mg/0.7 mL single-dose	Carton of 10	10-Digit: 0006-5073-02 11-Digit: 00006-5073-02

Please note: The NDC above is the billable NDC that appears on the carton.
NDC, National Drug Code.

Storage and handling

- Store prefilled syringes under refrigeration at 36°F to 46°F (2°C to 8°C)
- Keep the prefilled syringe in the original carton to protect from light until time of use
- ENFLONSIA may be kept at room temperature between 68°F to 77°F (20°C to 25°C) for a maximum of 48 hours. After removal from the refrigerator, ENFLONSIA must be used within 48 hours or discarded
- Do not freeze. Do not shake
- **30-month shelf life³**
- Package dimensions: Pack of 1: 44 x 105 x 29 mm, Pack of 10: 105 x 133 x 41 mm

Scan to learn more about ENFLONSIA.



Selected Safety Information (continued)

ENFLONSIA may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies. Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection.

The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

Before administering ENFLONSIA, please read the accompanying Prescribing Information.

The Patient Information also is available. For additional copies of the Prescribing Information, please call 800-672-6372, visit [ENFLONSIAhcp.com](https://www.enflonsiahcp.com), or contact your Merck representative.

References: 1. Centers for Disease Control and Prevention. ACIP Recommendation. Updated August 8, 2025. Accessed August 21, 2025. <https://www.cdc.gov/acip/vaccine-recommendations/index.html> 2. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement. *Pediatrics*. 2025; doi:10.1542/peds.2025-073923 3. US Food & Drug Administration Center for Drug Evaluation and Research. BLA Approval Letter. Published June 9, 2025. Accessed October 21, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/761432Orig1s000Approv.pdf



Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA
and its affiliates. All rights reserved. US-RSM-00151 11/25

